SummaryThis study compared the predicted effect-site concentration of propofol at loss and recovery of consciousness when using target-controlled infusion devices with the same pharmacokinetic model (Marsh) but a different plasma effect-site equilibration rate constant (k e0 ), the Diprifusor TM (k e0 0.26 min
À1) and Base Primea TM (k e0 1.21 min
À1). We studied 60 female patients undergoing minor gynaecological surgery under general anaesthesia. Although the total dose of propofol and time until loss of consciousness were comparable, the effect-site concentration at loss of consciousness was significantly lower with the Diprifusor than with the Base Primea (1.2 (0.3) lg.ml À1 vs 4.5 (0.9) lg.ml
À1, respectively, p < 0.001). The effect-site concentration at recovery of consciousness was significantly higher with the Diprifusor than with the Base Primea (1.8 (0.4) lg.ml À1 vs 1.5 (0.2) lg.ml
À1, respectively, p = 0.01). In conclusion, the effect-site concentration of propofol differs depending on the k e0 , despite the use of the same pharmacokinetic model. Therefore, the k e0 should be considered when predicting loss and recovery of consciousness based on the effect-site concentration of propofol. Target-controlled infusion (TCI) systems control the infusion rate of intravenous drugs according to predetermined pharmacokinetic profiles targeting plasma or effect-site concentration of the drug. After intravenous administration, the plasma concentration of a drug gradually equilibrates with its effect-site concentration. The rate of equilibration between plasma and effect-site concentration depends on the rate of transfer of the drug from the plasma to the effect-site [1]. The time course of equilibration between plasma and effect-site concentrations can be mathematically described by a first-order rate constant, known as the plasma effect-site equilibration rate constant (k e0 ), which can be used to estimate effect-site concentration [2].There are currently several commercial TCI devices designed for the infusion of propofol, such as the Diprifusor TM (AstraZeneca, Macclesfield, UK) and Base Primea TM (Fresenius-Vial, Br ezins, France). The 1232